- Cancer drugmaker
- Incyte's stock was down as much as 22% before markets opened on Friday morning, while Merck's was down a little more than 1%.
- Cancer immunotherapy works by harnessing the body's immune system to treat cancer.
- The trial was looking to see if combining two drugs — Merck's PD1 checkpoint inhibitor and Incyte's IDO1 inhibitor — that both essentially take the brake off the immune system to go after the cancer cells in people with metastatic melanoma could work even better than Merck's drug alone.
ADVERTISEMENT
A cancer drugmaker just failed a key trial and its stock is crashing (INCY, MRK)
Cancer drugmaker Incyte said on Friday that a key trial combining its cancer immunotherapy drug with a blockbuster drug from Merck failed in a late-stage trial.
ADVERTISEMENT
Recommended articles
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
Africa's gaming gold rush: Unveiling the surge in online gambling
Seven African countries added to Meta's AI service coverage
10 African countries with the lowest inflation rates in 2024
Davido launches his label Nine+ in partnership with UnitedMasters
Nigeria's economic ranking drops to fourth in Africa
Moscow inaugurates its House of Africa
The CBN justifies $2b billion loss in forex, dispelling Naira defense claims
10 best airports in Africa in 2024
